• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of thoraxThoraxInstructions for authorsInstructions for authors
Thorax. Dec 2001; 56(Suppl 4): iv1–iv64.
PMCID: PMC1765992

BTS Guidelines for the Management of Community Acquired Pneumonia in Adults

Full Text

The Full Text of this article is available as a PDF (553K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000 Aug;31(2):347–382. [PubMed]
  • Niederman MS, Bass JB, Jr, Campbell GD, Fein AM, Grossman RF, Mandell LA, Marrie TJ, Sarosi GA, Torres A, Yu VL. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis. 1993 Nov;148(5):1418–1426. [PubMed]
  • Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis. 2000 Aug;31(2):383–421. [PubMed]
  • Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000 May 22;160(10):1399–1408. [PubMed]
  • Macfarlane J. An overview of community acquired pneumonia with lessons learned from the British Thoracic Society Study. Semin Respir Infect. 1994 Sep;9(3):153–165. [PubMed]
  • Macfarlane JT, Finch RG, Ward MJ, Macrae AD. Hospital study of adult community-acquired pneumonia. Lancet. 1982 Jul 31;2(8292):255–258. [PubMed]
  • White RJ, Blainey AD, Harrison KJ, Clarke SK. Causes of pneumonia presenting to a district general hospital. Thorax. 1981 Aug;36(8):566–570. [PMC free article] [PubMed]
  • Venkatesan P, Gladman J, Macfarlane JT, Barer D, Berman P, Kinnear W, Finch RG. A hospital study of community acquired pneumonia in the elderly. Thorax. 1990 Apr;45(4):254–258. [PMC free article] [PubMed]
  • McNabb WR, Shanson DC, Williams TD, Lant AF. Adult community-acquired pneumonia in central London. J R Soc Med. 1984 Jul;77(7):550–555. [PMC free article] [PubMed]
  • Impallomeni M, Galletly NP, Wort SJ, Starr JM, Rogers TR. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ. 1995 Nov 18;311(7016):1345–1346. [PMC free article] [PubMed]
  • Starr JM, Rogers TR, Impallomeni M. Hospital-acquired Clostridium difficile diarrhoea and herd immunity. Lancet. 1997 Feb 8;349(9049):426–428. [PubMed]
  • McNulty C, Logan M, Donald IP, Ennis D, Taylor D, Baldwin RN, Bannerjee M, Cartwright KA. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother. 1997 Nov;40(5):707–711. [PubMed]
  • Tang CM, Macfarlane JT. Early management of younger adults dying of community acquired pneumonia. Respir Med. 1993 May;87(4):289–294. [PubMed]
  • Woodhead MA, Macfarlane JT, Rodgers FG, Laverick A, Pilkington R, Macrae AD. Aetiology and outcome of severe community-acquired pneumonia. J Infect. 1985 May;10(3):204–210. [PubMed]
  • Hirani NA, Macfarlane JT. Impact of management guidelines on the outcome of severe community acquired pneumonia. Thorax. 1997 Jan;52(1):17–21. [PMC free article] [PubMed]
  • Kinnear WJ, Finch RG, Pilkington R, Macfarlane JT. Nosocomial lower respiratory tract infections in surgical wards. Thorax. 1990 Mar;45(3):187–189. [PMC free article] [PubMed]
  • Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax. 1995 May;50(5):543–547. [PMC free article] [PubMed]
  • Almirall J, Morató I, Riera F, Verdaguer A, Priu R, Coll P, Vidal J, Murgui L, Valls F, Catalan F, et al. Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study. Eur Respir J. 1993 Jan;6(1):14–18. [PubMed]
  • Steinhoff D, Lode H, Ruckdeschel G, Heidrich B, Rolfs A, Fehrenbach FJ, Mauch H, Höffken G, Wagner J. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis. 1996 Jun;22(6):958–964. [PubMed]
  • Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, Segev S, Wijnands G. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J. 1995 Dec;8(12):1999–2007. [PubMed]
  • Lieberman D, Schlaeffer F, Boldur I, Lieberman D, Horowitz S, Friedman MG, Leiononen M, Horovitz O, Manor E, Porath A. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax. 1996 Feb;51(2):179–184. [PMC free article] [PubMed]
  • Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med. 1996 Nov;101(5):508–515. [PubMed]
  • Macfarlane J, Lewis SA, Macfarlane R, Holmes W. Contemporary use of antibiotics in 1089 adults presenting with acute lower respiratory tract illness in general practice in the U.K.: implications for developing management guidelines. Respir Med. 1997 Aug;91(7):427–434. [PubMed]
  • Torres A, Ausina V. Empirical treatment of nonsevere community-acquired pneumonia: still a difficult issue. Eur Respir J. 1995 Dec;8(12):1996–1998. [PubMed]
  • Hart CA. Antibiotic resistance: an increasing problem?. It always has been, but there are things we can do. BMJ. 1998 Apr 25;316(7140):1255–1256. [PMC free article] [PubMed]
  • Macfarlane J. Lower respiratory tract infection and pneumonia in the community. Semin Respir Infect. 1999 Jun;14(2):151–162. [PubMed]
  • Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet. 1987 Mar 21;1(8534):671–674. [PubMed]
  • Melbye H, Straume B, Aasebø U, Brox J. The diagnosis of adult pneumonia in general practice. The diagnostic value of history, physical examination and some blood tests. Scand J Prim Health Care. 1988 May;6(2):111–117. [PubMed]
  • Diehr P, Wood RW, Bushyhead J, Krueger L, Wolcott B, Tompkins RK. Prediction of pneumonia in outpatients with acute cough--a statistical approach. J Chronic Dis. 1984;37(3):215–225. [PubMed]
  • Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis. 1989 Jul-Aug;11(4):586–599. [PubMed]
  • Eccles M, Clapp Z, Grimshaw J, Adams PC, Higgins B, Purves I, Russell I. North of England evidence based guidelines development project: methods of guideline development. BMJ. 1996 Mar 23;312(7033):760–762. [PMC free article] [PubMed]
  • Woodhead M, Macfarlane J. Local antibiotic guidelines for adult community-acquired pneumonia (CAP): a survey of UK hospital practice in 1999. J Antimicrob Chemother. 2000 Jul;46(1):141–143. [PubMed]
  • Sackett DL, Wennberg JE. Choosing the best research design for each question. BMJ. 1997 Dec 20;315(7123):1636–1636. [PMC free article] [PubMed]
  • Sackett DL. Bias in analytic research. J Chronic Dis. 1979;32(1-2):51–63. [PubMed]
  • Jaeschke R, Guyatt G, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1994 Feb 2;271(5):389–391. [PubMed]
  • Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ. Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA. 1995 Dec 13;274(22):1800–1804. [PubMed]
  • Gleason PP, Kapoor WN, Stone RA, Lave JR, Obrosky DS, Schulz R, Singer DE, Coley CM, Marrie TJ, Fine MJ. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA. 1997 Jul 2;278(1):32–39. [PubMed]
  • Gilbert K, Gleason PP, Singer DE, Marrie TJ, Coley CM, Obrosky DS, Lave JR, Kapoor WN, Fine MJ. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. Am J Med. 1998 Jan;104(1):17–27. [PubMed]
  • Nathwani D, Rubinstein E, Barlow G, Davey P. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin Infect Dis. 2001 Mar 1;32(5):728–741. [PubMed]
  • Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Karkola K, Korppi M, Kurki S, Rönnberg PR, Seppä A, Soimakallio S, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol. 1993 May 1;137(9):977–988. [PubMed]
  • Foy HM, Cooney MK, Allan I, Kenny GE. Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. JAMA. 1979 Jan 19;241(3):253–258. [PubMed]
  • Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet. 1993 Feb 27;341(8844):511–514. [PubMed]
  • Marrie TJ. Epidemiology of community-acquired pneumonia in the elderly. Semin Respir Infect. 1990 Dec;5(4):260–268. [PubMed]
  • Marston BJ, Plouffe JF, File TM, Jr, Hackman BA, Salstrom SJ, Lipman HB, Kolczak MS, Breiman RF. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med. 1997 Aug 11;157(15):1709–1718. [PubMed]
  • Lave JR, Fine MJ, Sankey SS, Hanusa BH, Weissfeld LA, Kapoor WN. Hospitalized pneumonia. Outcomes, treatment patterns, and costs in urban and rural areas. J Gen Intern Med. 1996 Jul;11(7):415–421. [PubMed]
  • Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J. 1997 Jul;10(7):1530–1534. [PubMed]
  • Foy HM, Cooney MK, McMahan R, Grayston JT. Viral and mycoplasmal pneumonia in a prepaid medical care group during an eight-year period. Am J Epidemiol. 1973 Feb;97(2):93–102. [PubMed]
  • Minogue MF, Coley CM, Fine MJ, Marrie TJ, Kapoor WN, Singer DE. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. Ann Emerg Med. 1998 Mar;31(3):376–380. [PubMed]
  • Torres A, Serra-Batlles J, Ferrer A, Jiménez P, Celis R, Cobo E, Rodriguez-Roisin R. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis. 1991 Aug;144(2):312–318. [PubMed]
  • Woodhead M. Management of pneumonia in the outpatient setting. Semin Respir Infect. 1998 Mar;13(1):8–16. [PubMed]
  • Lim WS, Macfarlane JT, Boswell TC, Harrison TG, Rose D, Leinonen M, Saikku P. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001 Apr;56(4):296–301. [PMC free article] [PubMed]
  • Karalus NC, Cursons RT, Leng RA, Mahood CB, Rothwell RP, Hancock B, Cepulis S, Wawatai M, Coleman L. Community acquired pneumonia: aetiology and prognostic index evaluation. Thorax. 1991 Jun;46(6):413–418. [PMC free article] [PubMed]
  • Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, Jackson R, Schousboe M, Frampton C, Hutton S, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax. 1996 Oct;51(10):1010–1016. [PMC free article] [PubMed]
  • Lim I, Shaw DR, Stanley DP, Lumb R, McLennan G. A prospective hospital study of the aetiology of community-acquired pneumonia. Med J Aust. 1989 Jul 17;151(2):87–91. [PubMed]
  • Alkhayer M, Jenkins PF, Harrison BD. The outcome of community acquired pneumonia treated on the intensive care unit. Respir Med. 1990 Jan;84(1):13–16. [PubMed]
  • Leroy O, Georges H, Beuscart C, Guery B, Coffinier C, Vandenbussche C, Thevenin D, Beaucaire G. Severe community-acquired pneumonia in ICUs: prospective validation of a prognostic score. Intensive Care Med. 1996 Dec;22(12):1307–1314. [PubMed]
  • Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest. 1994 May;105(5):1487–1495. [PubMed]
  • Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther. 1998 Jul-Aug;20(4):820–837. [PubMed]
  • Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, Torres A. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med. 1999 Aug;160(2):397–405. [PubMed]
  • Ausina V, Coll P, Sambeat M, Puig I, Condom MJ, Luquin M, Ballester F, Prats G. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. Eur J Clin Microbiol Infect Dis. 1988 Jun;7(3):342–347. [PubMed]
  • Logroscino CD, Penza O, Locicero S, Losito G, Nardini S, Bertoli L, Cioffi R, Del Prato B. Community-acquired pneumonia in adults: a multicentric observational AIPO study. Monaldi Arch Chest Dis. 1999 Feb;54(1):11–17. [PubMed]
  • Leroy O, Guilley J, Georges H, Choisy P, Guery B, Alfandari S, Beaucaire G. Effect of hospital-acquired ventilator-associated pneumonia on mortality of severe community-acquired pneumonia. J Crit Care. 1999 Mar;14(1):12–19. [PubMed]
  • Ostergaard L, Andersen PL. Etiology of community-acquired pneumonia. Evaluation by transtracheal aspiration, blood culture, or serology. Chest. 1993 Nov;104(5):1400–1407. [PubMed]
  • Torres A, Dorca J, Zalacaín R, Bello S, El-Ebiary M, Molinos L, Arévalo M, Blanquer J, Celis R, Iriberri M, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med. 1996 Nov;154(5):1456–1461. [PubMed]
  • Marrie TJ. Bacteraemic pneumococcal pneumonia: a continuously evolving disease. J Infect. 1992 May;24(3):247–255. [PubMed]
  • Marrie TJ, Durant H, Kwan C. Nursing home-acquired pneumonia. A case-control study. J Am Geriatr Soc. 1986 Oct;34(10):697–702. [PubMed]
  • Garb JL, Brown RB, Garb JR, Tuthill RW. Differences in etiology of pneumonias in nursing home and community patients. JAMA. 1978 Nov 10;240(20):2169–2172. [PubMed]
  • Drinka PJ, Gauerke C, Voeks S, Miller J, Schultz S, Krause P, Golubjatnikov R. Pneumonia in a nursing home. J Gen Intern Med. 1994 Nov;9(11):650–652. [PubMed]
  • Leroy O, Vandenbussche C, Coffinier C, Bosquet C, Georges H, Guery B, Thevenin D, Beaucaire G. Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data. Am J Respir Crit Care Med. 1997 Dec;156(6):1922–1929. [PubMed]
  • Sopena N, Sabrià-Leal M, Pedro-Botet ML, Padilla E, Dominguez J, Morera J, Tudela P. Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. Chest. 1998 May;113(5):1195–1200. [PubMed]
  • Stout JE, Yu VL. Legionellosis. N Engl J Med. 1997 Sep 4;337(10):682–687. [PubMed]
  • Mier L, Dreyfuss D, Darchy B, Lanore JJ, Djedaïni K, Weber P, Brun P, Coste F. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med. 1993;19(5):279–284. [PubMed]
  • Kim PE, Musher DM, Glezen WP, Rodriguez-Barradas MC, Nahm WK, Wright CE. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin Infect Dis. 1996 Jan;22(1):100–106. [PubMed]
  • Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men's shelters. Chest. 1991 Jan;99(1):147–151. [PubMed]
  • Hoge CW, Reichler MR, Dominguez EA, Bremer JC, Mastro TD, Hendricks KA, Musher DM, Elliott JA, Facklam RR, Breiman RF. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med. 1994 Sep 8;331(10):643–648. [PubMed]
  • Tan YK, Khoo KL, Chin SP, Ong YY. Aetiology and outcome of severe community-acquired pneumonia in Singapore. Eur Respir J. 1998 Jul;12(1):113–115. [PubMed]
  • Chan CH, Cohen M, Pang J. A prospective study of community-acquired pneumonia in Hong Kong. Chest. 1992 Feb;101(2):442–446. [PubMed]
  • Joseph CA, Dedman D, Birtles R, Watson JM, Bartlett CL. Legionnaires' disease surveillance: England and Wales, 1993. Commun Dis Rep CDR Rev. 1994 Sep 16;4(10):R109–R111. [PubMed]
  • Joseph CA, Hutchinson EJ, Dedman D, Birtles RJ, Watson JM, Bartlett CL. Legionnaires' disease surveillance: England and Wales 1994. Commun Dis Rep CDR Rev. 1995 Nov 10;5(12):R180–R183. [PubMed]
  • Newton LH, Joseph CA, Hutchinson EJ, Harrison TG, Watson JM, Bartlett CL. Legionnaires' disease surveillance: England and Wales, 1995. Commun Dis Rep CDR Rev. 1996 Oct 11;6(11):R151–R155. [PubMed]
  • Joseph CA, Harrison TG, Ilijic-Car D, Bartlett CL. Legionnaires' disease in residents of England and Wales: 1996. Commun Dis Rep CDR Rev. 1997 Oct 17;7(11):R153–R159. [PubMed]
  • Joseph CA, Harrison TG, Ilijic-Car D, Bartlett CL. Legionnaires' disease in residents of England and Wales: 1998. Commun Dis Public Health. 1999 Dec;2(4):280–284. [PubMed]
  • Saikku P, Wang SP, Kleemola M, Brander E, Rusanen E, Grayston JT. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis. 1985 May;151(5):832–839. [PubMed]
  • Kleemola M, Saikku P, Visakorpi R, Wang SP, Grayston JT. Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland. J Infect Dis. 1988 Feb;157(2):230–236. [PubMed]
  • Troy CJ, Peeling RW, Ellis AG, Hockin JC, Bennett DA, Murphy MR, Spika JS. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. JAMA. 1997 Apr 16;277(15):1214–1218. [PubMed]
  • Kauppinen MT, Saikku P, Kujala P, Herva E, Syrjälä H. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax. 1996 Feb;51(2):185–189. [PMC free article] [PubMed]
  • Wreghitt T. Chlamydial infection of the respiratory tract. Commun Dis Rep CDR Rev. 1993 Aug 13;3(9):R119–R124. [PubMed]
  • Pebody RG, Wall PG, Ryan MJ, Fairley C. Epidemiological features of Coxiella burnetii infection in England and Wales: 1984 to 1994. Commun Dis Rep CDR Rev. 1996 Aug 16;6(9):R128–R132. [PubMed]
  • Hutchinson EJ, Joseph CA, Zambon M, Fleming DM, Watson JM. Influenza surveillance in England and Wales: October 1995 to June 1996. Commun Dis Rep CDR Rev. 1996 Nov 8;6(12):R163–R169. [PubMed]
  • Connolly AM, Salmon RL, Lervy B, Williams DH. What are the complications of influenza and can they be prevented? Experience from the 1989 epidemic of H3N2 influenza A in general practice. BMJ. 1993 May 29;306(6890):1452–1454. [PMC free article] [PubMed]
  • Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA. 1997 Nov 5;278(17):1440–1445. [PubMed]
  • Spiteri MA, Cook DG, Clarke SW. Reliability of eliciting physical signs in examination of the chest. Lancet. 1988 Apr 16;1(8590):873–875. [PubMed]
  • Marrie TJ. Pneumonia in the elderly. Curr Opin Pulm Med. 1996 May;2(3):192–197. [PubMed]
  • Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990 Sep;69(5):307–316. [PubMed]
  • Farr BM, Kaiser DL, Harrison BD, Connolly CK. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. Thorax. 1989 Dec;44(12):1031–1035. [PMC free article] [PubMed]
  • Riquelme R, Torres A, el-Ebiary M, Mensa J, Estruch R, Ruiz M, Angrill J, Soler N. Community-acquired pneumonia in the elderly. Clinical and nutritional aspects. Am J Respir Crit Care Med. 1997 Dec;156(6):1908–1914. [PubMed]
  • Bohte R, Hermans J, van den Broek PJ. Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1996 Mar;15(3):201–205. [PubMed]
  • Marrie TJ. Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly. Arch Intern Med. 1993 Feb 22;153(4):488–494. [PubMed]
  • Helms CM, Viner JP, Sturm RH, Renner ED, Johnson W. Comparative features of pneumococcal, mycoplasmal, and Legionnaires' disease pneumonias. Ann Intern Med. 1979 Apr;90(4):543–547. [PubMed]
  • Helms CM, Wintermeyer LA, Zeitler RR, Larew RE, Massanari RM, Hall NH, Hausler WJ, Jr, Johnson W. An outbreak of community-acquired Legionnaires' disease pneumonia. Am J Public Health. 1984 Aug;74(8):835–836. [PMC free article] [PubMed]
  • Lieberman D, Porath A, Schlaeffer F, Lieberman D, Boldur I. Legionella species community-acquired pneumonia. A review of 56 hospitalized adult patients. Chest. 1996 May;109(5):1243–1249. [PubMed]
  • Granados A, Podzamczer D, Gudiol F, Manresa F. Pneumonia due to Legionella pneumophila and pneumococcal pneumonia: similarities and differences on presentation. Eur Respir J. 1989 Feb;2(2):130–134. [PubMed]
  • Falcó V, Fernández de Sevilla T, Alegre J, Ferrer A, Martínez Vázquez JM. Legionella pneumophila. A cause of severe community-acquired pneumonia. Chest. 1991 Oct;100(4):1007–1011. [PubMed]
  • Lieberman D, Ben-Yaakov M, Lazarovich Z, Porath A, Schlaeffer F, Lieberman D, Leinonen M, Saikku P, Horovitz O, Boldur I. Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients. Infection. 1996 Mar-Apr;24(2):109–114. [PubMed]
  • File TM, Jr, Plouffe JF, Jr, Breiman RF, Skelton SK. Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia. Clin Infect Dis. 1999 Aug;29(2):426–428. [PubMed]
  • Lieberman D, Lieberman D, Boldur I, Manor E, Hoffman S, Schlaeffer F, Porath A. Q-fever pneumonia in the Negev region of Israel: a review of 20 patients hospitalised over a period of one year. J Infect. 1995 Mar;30(2):135–140. [PubMed]
  • Caron F, Meurice JC, Ingrand P, Bourgoin A, Masson P, Roblot P, Patte F. Acute Q fever pneumonia: a review of 80 hospitalized patients. Chest. 1998 Sep;114(3):808–813. [PubMed]
  • Sobradillo V, Ansola P, Baranda F, Corral C. Q fever pneumonia: a review of 164 community-acquired cases in the Basque country. Eur Respir J. 1989 Mar;2(3):263–266. [PubMed]
  • Feldman C, Kallenbach JM, Levy H, Thorburn JR, Hurwitz MD, Koornhof HJ. Comparison of bacteraemic community-acquired lobar pneumonia due to Streptococcus pneumoniae and Klebsiella pneumoniae in an intensive care unit. Respiration. 1991;58(5-6):265–270. [PubMed]
  • Rudin ML, Michael JR, Huxley EJ. Community-acquired acinetobacter pneumonia. Am J Med. 1979 Jul;67(1):39–43. [PubMed]
  • Henderson A, Wall D. Streptococcus milleri liver abscess presenting as fulminant pneumonia. Aust N Z J Surg. 1993 Mar;63(3):237–240. [PubMed]
  • Goolam Mahomed A, Feldman C, Smith C, Promnitz DA, Kaka S. Does primary Streptococcus viridans pneumonia exist? S Afr Med J. 1992 Dec;82(6):432–434. [PubMed]
  • Metlay JP, Schulz R, Li YH, Singer DE, Marrie TJ, Coley CM, Hough LJ, Obrosky DS, Kapoor WN, Fine MJ. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med. 1997 Jul 14;157(13):1453–1459. [PubMed]
  • Marrie TJ, Haldane EV, Faulkner RS, Durant H, Kwan C. Community-acquired pneumonia requiring hospitalization. Is it different in the elderly? J Am Geriatr Soc. 1985 Oct;33(10):671–680. [PubMed]
  • Marrie TJ, Blanchard W. A comparison of nursing home-acquired pneumonia patients with patients with community-acquired pneumonia and nursing home patients without pneumonia. J Am Geriatr Soc. 1997 Jan;45(1):50–55. [PubMed]
  • Macfarlane JT, Miller AC, Roderick Smith WH, Morris AH, Rose DH. Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis. Thorax. 1984 Jan;39(1):28–33. [PMC free article] [PubMed]
  • Prout S, Potgieter PD, Forder AA, Moodie JW, Matthews J. Acute community-acquired pneumonias. S Afr Med J. 1983 Sep 17;64(12):443–446. [PubMed]
  • Kauppinen MT, Lähde S, Syrjälä H. Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia. Arch Intern Med. 1996 Sep 9;156(16):1851–1856. [PubMed]
  • Gikas A, Kofteridis D, Bouros D, Voloudaki A, Tselentis Y, Tsaparas N. Q fever pneumonia: appearance on chest radiographs. Radiology. 1999 Feb;210(2):339–343. [PubMed]
  • Macfarlane J, Rose D. Radiographic features of staphylococcal pneumonia in adults and children. Thorax. 1996 May;51(5):539–540. [PMC free article] [PubMed]
  • Korvick JA, Hackett AK, Yu VL, Muder RR. Klebsiella pneumonia in the modern era: clinicoradiographic correlations. South Med J. 1991 Feb;84(2):200–204. [PubMed]
  • Tanaka N, Matsumoto T, Kuramitsu T, Nakaki H, Ito K, Uchisako H, Miura G, Matsunaga N, Yamakawa K. High resolution CT findings in community-acquired pneumonia. J Comput Assist Tomogr. 1996 Jul-Aug;20(4):600–608. [PubMed]
  • Syrjälä H, Broas M, Suramo I, Ojala A, Lähde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis. 1998 Aug;27(2):358–363. [PubMed]
  • Reittner P, Müller NL, Heyneman L, Johkoh T, Park JS, Lee KS, Honda O, Tomiyama N. Mycoplasma pneumoniae pneumonia: radiographic and high-resolution CT features in 28 patients. AJR Am J Roentgenol. 2000 Jan;174(1):37–41. [PubMed]
  • Beall DP, Scott WW, Jr, Kuhlman JE, Hofmann LV, Moore RD, Mundy LM. Utilization of computed tomography in patients hospitalized with community-acquired pneumonia. Md Med J. 1998 Aug;47(4):182–187. [PubMed]
  • Mittl RL, Jr, Schwab RJ, Duchin JS, Goin JE, Albeida SM, Miller WT. Radiographic resolution of community-acquired pneumonia. Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):630–635. [PubMed]
  • Jay SJ, Johanson WG, Jr, Pierce AK. The radiographic resolution of Streptococcus pneumoniae pneumonia. N Engl J Med. 1975 Oct 16;293(16):798–801. [PubMed]
  • Granet KM, Wallach SL, Horvath K, Jaeger J. Chest radiographs in patients with community-acquired pneumonia. N J Med. 1996 Jun;93(6):37–41. [PubMed]
  • Holmberg H, Kragsbjerg P. Association of pneumonia and lung cancer: the value of convalescent chest radiography and follow-up. Scand J Infect Dis. 1993;25(1):93–100. [PubMed]
  • Gibson SP, Weir DC, Burge PS. A prospective audit of the value of fibre optic bronchoscopy in adults admitted with community acquired pneumonia. Respir Med. 1993 Feb;87(2):105–109. [PubMed]
  • Holmberg H, Bodin L, Jönsson I, Krook A. Rapid aetiological diagnosis of pneumonia based on routine laboratory features. Scand J Infect Dis. 1990;22(5):537–545. [PubMed]
  • Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest. 1995 Nov;108(5):1288–1291. [PubMed]
  • Hansson LO, Hedlund JU, Ortqvist AB. Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia. Scand J Clin Lab Invest. 1997 Apr;57(2):111–118. [PubMed]
  • Ortqvist A, Hedlund J, Wretlind B, Carlström A, Kalin M. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis. 1995;27(5):457–462. [PubMed]
  • Sanyal S, Smith PR, Saha AC, Gupta S, Berkowitz L, Homel P. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med. 1999 Jul;160(1):346–348. [PubMed]
  • Menéndez R, Córdoba J, de La Cuadra P, Cremades MJ, López-Hontagas JL, Salavert M, Gobernado M. Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med. 1999 Jun;159(6):1868–1873. [PubMed]
  • Ewig S, Bauer T, Hasper E, Marklein G, Kubini R, Lüderitz B. Value of routine microbial investigation in community-acquired pneumonia treated in a tertiary care center. Respiration. 1996;63(3):164–169. [PubMed]
  • Woodhead MA, Arrowsmith J, Chamberlain-Webber R, Wooding S, Williams I. The value of routine microbial investigation in community-acquired pneumonia. Respir Med. 1991 Jul;85(4):313–317. [PubMed]
  • Reed WW, Byrd GS, Gates RH, Jr, Howard RS, Weaver MJ. Sputum gram's stain in community-acquired pneumococcal pneumonia. A meta-analysis. West J Med. 1996 Oct;165(4):197–204. [PMC free article] [PubMed]
  • Rein MF, Gwaltney JM, Jr, O'Brien WM, Jennings RH, Mandell GL. Accuracy of Gram's stain in identifying pneumococci in sputum. JAMA. 1978 Jun 23;239(25):2671–2673. [PubMed]
  • Fine MJ, Orloff JJ, Rihs JD, Vickers RM, Kominos S, Kapoor WN, Arena VC, Yu VL. Evaluation of housestaff physicians' preparation and interpretation of sputum Gram stains for community-acquired pneumonia. J Gen Intern Med. 1991 May-Jun;6(3):189–198. [PubMed]
  • Croce MA, Fabian TC, Waddle-Smith L, Melton SM, Minard G, Kudsk KA, Pritchard FE. Utility of Gram's stain and efficacy of quantitative cultures for posttraumatic pneumonia: a prospective study. Ann Surg. 1998 May;227(5):743–755. [PMC free article] [PubMed]
  • Venkatesan P, Macfarlane JT. Role of pneumococcal antigen in the diagnosis of pneumococcal pneumonia. Thorax. 1992 May;47(5):329–331. [PMC free article] [PubMed]
  • Farrington M, Rubenstein D. Antigen detection in pneumococcal pneumonia. J Infect. 1991 Sep;23(2):109–116. [PubMed]
  • Jalonen E, Paton JC, Koskela M, Kerttula Y, Leinonen M. Measurement of antibody responses to pneumolysin--a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia. J Infect. 1989 Sep;19(2):127–134. [PubMed]
  • Birtles RJ, Harrison TG, Samuel D, Taylor AG. Evaluation of urinary antigen ELISA for diagnosing Legionella pneumophila serogroup 1 infection. J Clin Pathol. 1990 Aug;43(8):685–690. [PMC free article] [PubMed]
  • Boswell TC, Marshall LE, Kudesia G. False-positive legionella titres in routine clinical serology testing detected by absorption with campylobacter: implications for the serological diagnosis of legionnaires' disease. J Infect. 1996 Jan;32(1):23–26. [PubMed]
  • Sillis M, White P, Caul EO, Paul ID, Treharne JD. The differentiation of Chlamydia species by antigen detection in sputum specimens from patients with community-acquired acute respiratory infections. J Infect. 1992 Jul;25 (Suppl 1):77–86. [PubMed]
  • Garnett P, Brogan O, Lafong C, Fox C. Comparison of throat swabs with sputum specimens for the detection of Chlamydia pneumoniae antigen by direct immunofluorescence. J Clin Pathol. 1998 Apr;51(4):309–311. [PMC free article] [PubMed]
  • Boman J, Allard A, Persson K, Lundborg M, Juto P, Wadell G. Rapid diagnosis of respiratory Chlamydia pneumoniae infection by nested touchdown polymerase chain reaction compared with culture and antigen detection by EIA. J Infect Dis. 1997 Jun;175(6):1523–1526. [PubMed]
  • Sillis M, Wreghitt TG, Paul ID, Caul EO. Chlamydial respiratory infections. Don't get bogged down by differentiating species. BMJ. 1993 Jul 3;307(6895):62–63. [PMC free article] [PubMed]
  • Kutlin A, Tsumura N, Emre U, Roblin PM, Hammerschlag MR. Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infection. Clin Diagn Lab Immunol. 1997 Mar;4(2):213–216. [PMC free article] [PubMed]
  • Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, Niederman MS, Torres A. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med. 1998 Oct;158(4):1102–1108. [PubMed]
  • Meyer RJ, Town GI, Harrè E, Koning M, Hurrell M, Beard ME, Chambers ST. An audit of the assessment and management of adults admitted to Christchurch Hospital with community acquired pneumonia. N Z Med J. 1997 Sep 26;110(1052):349–352. [PubMed]
  • Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med. 1991 Sep 15;115(6):428–436. [PubMed]
  • Ewig S, Bauer T, Hasper E, Pizzulli L, Kubini R, Lüderitz B. Prognostic analysis and predictive rule for outcome of hospital-treated community-acquired pneumonia. Eur Respir J. 1995 Mar;8(3):392–397. [PubMed]
  • Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996 Jan 10;275(2):134–141. [PubMed]
  • Fine MJ, Singer DE, Hanusa BH, Lave JR, Kapoor WN. Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. Am J Med. 1993 Feb;94(2):153–159. [PubMed]
  • Hedlund J, Kalin M, Ortqvist A. Recurrence of pneumonia in middle-aged and elderly adults after hospital-treated pneumonia: aetiology and predisposing conditions. Scand J Infect Dis. 1997;29(4):387–392. [PubMed]
  • Conte HA, Chen YT, Mehal W, Scinto JD, Quagliarello VJ. A prognostic rule for elderly patients admitted with community-acquired pneumonia. Am J Med. 1999 Jan;106(1):20–28. [PubMed]
  • Janssens JP, Gauthey L, Herrmann F, Tkatch L, Michel JP. Community-acquired pneumonia in older patients. J Am Geriatr Soc. 1996 May;44(5):539–544. [PubMed]
  • Riquelme R, Torres A, El-Ebiary M, de la Bellacasa JP, Estruch R, Mensa J, Fernández-Solá J, Hernández C, Rodriguez-Roisin R. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med. 1996 Nov;154(5):1450–1455. [PubMed]
  • Leroy O, Devos P, Guery B, Georges H, Vandenbussche C, Coffinier C, Thévenin D, Beaucaire G. Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs. Chest. 1999 Jul;116(1):157–165. [PubMed]
  • Fine MJ, Hanusa BH, Lave JR, Singer DE, Stone RA, Weissfeld LA, Coley CM, Marrie TJ, Kapoor WN. Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia. J Gen Intern Med. 1995 Jul;10(7):359–368. [PubMed]
  • Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonia. Etiology, prognosis, and treatment. Am Rev Respir Dis. 1990 Aug;142(2):369–373. [PubMed]
  • Leroy O, Santré C, Beuscart C, Georges H, Guery B, Jacquier JM, Beaucaire G. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med. 1995 Jan;21(1):24–31. [PubMed]
  • Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997 Jan 23;336(4):243–250. [PubMed]
  • Ortqvist A, Hedlund J, Grillner L, Jalonen E, Kallings I, Leinonen M, Kalin M. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J. 1990 Nov;3(10):1105–1113. [PubMed]
  • van Eeden SF, Coetzee AR, Joubert JR. Community-acquired pneumonia--factors influencing intensive care admission. S Afr Med J. 1988 Jan 23;73(2):77–81. [PubMed]
  • Qureshi KN, Hodkinson HM. Evaluation of a ten-question mental test in the institutionalized elderly. Age Ageing. 1974 Aug;3(3):152–157. [PubMed]
  • Gómez J, Baños V, Ruiz Gómez J, Soto MC, Muñoz L, Nuñez ML, Canteras M, Valdés M. Prospective study of epidemiology and prognostic factors in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1996 Jul;15(7):556–560. [PubMed]
  • Feldman C, Kallenbach JM, Levy H, Reinach SG, Hurwitz MD, Thorburn JR, Koornhof HJ. Community-acquired pneumonia of diverse aetiology: prognostic features in patients admitted to an intensive care unit and a "severity of illness" core. Intensive Care Med. 1989;15(5):302–307. [PubMed]
  • Hasley PB, Albaum MN, Li YH, Fuhrman CR, Britton CA, Marrie TJ, Singer DE, Coley CM, Kapoor WN, Fine MJ. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? Arch Intern Med. 1996 Oct 28;156(19):2206–2212. [PubMed]
  • Marras TK, Chan CK. Use of guidelines in treating community-acquired pneumonia. Chest. 1998 Jun;113(6):1689–1694. [PubMed]
  • Atlas SJ, Benzer TI, Borowsky LH, Chang Y, Burnham DC, Metlay JP, Halm EA, Singer DE. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med. 1998 Jun 22;158(12):1350–1356. [PubMed]
  • Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA. 2000 Feb 9;283(6):749–755. [PubMed]
  • Farr BM, Woodhead MA, Macfarlane JT, Bartlett CL, McCraken JS, Wadsworth J, Miller DL. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med. 2000 May;94(5):422–427. [PubMed]
  • Tydeman DE, Chandler AR, Graveling BM, Culot A, Harrison BD. An investigation into the effects of exercise tolerance training on patients with chronic airways obstruction. Physiotherapy. 1984 Jul 10;70(7):261–264. [PubMed]
  • LaCroix AZ, Lipson S, Miles TP, White L. Prospective study of pneumonia hospitalizations and mortality of U.S. older people: the role of chronic conditions, health behaviors, and nutritional status. Public Health Rep. 1989 Jul-Aug;104(4):350–360. [PMC free article] [PubMed]
  • Fulmer JD, Snider GL. American College of Chest Physicians/National Heart, Lung, and Blood Institute National Conference on Oxygen Therapy. Heart Lung. 1984 Sep;13(5):550–562. [PubMed]
  • Jeffrey AA, Warren PM, Flenley DC. Acute hypercapnic respiratory failure in patients with chronic obstructive lung disease: risk factors and use of guidelines for management. Thorax. 1992 Jan;47(1):34–40. [PMC free article] [PubMed]
  • Björkqvist M, Wiberg B, Bodin L, Bárány M, Holmberg H. Bottle-blowing in hospital-treated patients with community-acquired pneumonia. Scand J Infect Dis. 1997;29(1):77–82. [PubMed]
  • Confalonieri M, Potena A, Carbone G, Porta RD, Tolley EA, Umberto Meduri G. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1585–1591. [PubMed]
  • Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644–1655. [PubMed]
  • Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest. 1993 Aug;104(2):389–392. [PubMed]
  • Riley TV. Clostridium difficile: a pathogen of the nineties. Eur J Clin Microbiol Infect Dis. 1998 Mar;17(3):137–141. [PubMed]
  • Zadik PM, Moore AP. Antimicrobial associations of an outbreak of diarrhoea due to Clostridium difficile. J Hosp Infect. 1998 Jul;39(3):189–193. [PubMed]
  • MacGowan AP, Feeney R, Brown I, McCulloch SY, Reeves DS, Lovering AM. Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea. J Antimicrob Chemother. 1997 Apr;39(4):537–541. [PubMed]
  • Settle CD, Wilcox MH, Fawley WN, Corrado OJ, Hawkey PM. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther. 1998 Dec;12(12):1217–1223. [PubMed]
  • Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother. 1998 May;41 (Suppl 100):21–27. [PubMed]
  • Ludlam H, Brown N, Sule O, Redpath C, Coni N, Owen G. An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea. Age Ageing. 1999 Oct;28(6):578–580. [PubMed]
  • Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998 Sep;40(1):1–15. [PubMed]
  • Wilcox MH. Respiratory antibiotic use and clostridium difficile infection: is it the drugs or is it the doctors? Thorax. 2000 Aug;55(8):633–634. [PMC free article] [PubMed]
  • Boswell TC, Nye KJ, Smith EG. Increased incidence of Clostridium difficile infection. J Hosp Infect. 1998 May;39(1):78–79. [PubMed]
  • Powell M, Yeo SF, Seymour A, Yuan M, Williams JD, Fah YS. Antimicrobial resistance in Haemophilus influenzae from England and Scotland in 1991. J Antimicrob Chemother. 1992 May;29(5):547–554. [PubMed]
  • Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens--findings of the Alexander Project 1992-1996. J Chemother. 1999 Feb;11 (Suppl 1):5–21. [PubMed]
  • Andrews J, Ashby J, Jevons G, Marshall T, Lines N, Wise R. A comparison of antimicrobial resistance rates in Gram-positive pathogens isolated in the UK from October 1996 to January 1997 and October 1997 to January 1998. J Antimicrob Chemother. 2000 Mar;45(3):285–293. [PubMed]
  • Johnson AP. Antibiotic resistance among clinically important gram-positive bacteria in the UK. J Hosp Infect. 1998 Sep;40(1):17–26. [PubMed]
  • Pallares R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martin R, Gudiol F. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995 Aug 24;333(8):474–480. [PubMed]
  • Einarsson S, Kristjansson M, Kristinsson KG, Kjartansson G, Jonsson S. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case-control study. Scand J Infect Dis. 1998;30(3):253–256. [PubMed]
  • Pallares R, Viladrich PF, Liñares J, Cabellos C, Gudiol F. Impact of antibiotic resistance on chemotherapy for pneumococcal infections. Microb Drug Resist. 1998 Winter;4(4):339–347. [PubMed]
  • Garau J, Aguilar L, Rodríguez-Créixems M, Dal-ré R, Pérez-Trallero E, Rodríguez M, Bouza E. Influence of comorbidity and severity on the clinical outcome of bacteremic pneumococcal pneumonia treated with beta-lactam monotherapy. J Chemother. 1999 Aug;11(4):266–272. [PubMed]
  • Ewig S, Kleinfeld T, Bauer T, Seifert K, Schäfer H, Göke N. Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population. Eur Respir J. 1999 Aug;14(2):370–375. [PubMed]
  • Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 1999 Jul 22;341(4):233–239. [PubMed]
  • Nielsen K, Bangsborg JM, Høiby N. Susceptibility of Legionella species to five antibiotics and development of resistance by exposure to erythromycin, ciprofloxacin, and rifampicin. Diagn Microbiol Infect Dis. 2000 Jan;36(1):43–48. [PubMed]
  • Honeybourne D. Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr Opin Pulm Med. 1997 Mar;3(2):170–174. [PubMed]
  • Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J. 1999 Jul;14(1):221–229. [PubMed]
  • Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother. 1997 May;9 (Suppl 3):38–44. [PubMed]
  • Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998 Jan;26(1):1–12. [PubMed]
  • Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998 Jan 14;279(2):125–129. [PubMed]
  • Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Wong FA, Corrado M. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother. 1998 May;42(5):1098–1104. [PMC free article] [PubMed]
  • Anderson G, Esmonde TS, Coles S, Macklin J, Carnegie C. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother. 1991 Feb;27 (Suppl A):117–124. [PubMed]
  • Chien SM, Pichotta P, Siepman N, Chan CK. Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group. Chest. 1993 Mar;103(3):697–701. [PubMed]
  • Bohte R, van't Wout JW, Lobatto S, Blussé van Oud Alblas A, Boekhout M, Nauta EH, Hermans J, van den Broek PJ. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1995 Mar;14(3):182–187. [PubMed]
  • Chan R, Hemeryck L, O'Regan M, Clancy L, Feely J. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. BMJ. 1995 May 27;310(6991):1360–1362. [PMC free article] [PubMed]
  • Plouffe JF, Herbert MT, File TM, Jr, Baird I, Parsons JN, Kahn JB, Rielly-Gauvin KT. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. Antimicrob Agents Chemother. 1996 May;40(5):1175–1179. [PMC free article] [PubMed]
  • File TM, Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997 Sep;41(9):1965–1972. [PMC free article] [PubMed]
  • Van den Brande P, Vondra V, Vogel F, Schlaeffer F, Staley H, Holmes C. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest. 1997 Aug;112(2):406–415. [PubMed]
  • O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis. 1998 Dec;17(12):828–833. [PubMed]
  • Rovira E, Martínez-Moragón E, Belda A, Gonzalvo F, Ripollés F, Pascual JM. Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime. Respiration. 1999;66(5):413–418. [PubMed]
  • Bartoloni A, Strohmeyer M, Corti G, Buonomini MI, Franchino L, Romanelli G, Moretti AM, De Vizzi GB, Petraglia A, Mancini P, et al. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Drugs Exp Clin Res. 1999;25(6):243–252. [PubMed]
  • Baumgartner JD, Glauser MP. Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia. Am J Med. 1984 Oct 19;77(4C):54–58. [PubMed]
  • Fredlund H, Bodin L, Bäck E, Holmberg H, Krook A, Rydman H. Antibiotic therapy in pneumonia: a comparative study of parenteral and oral administration of penicillin. Scand J Infect Dis. 1987;19(4):459–466. [PubMed]
  • Zuck P, Rio Y, Ichou F. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother. 1990 Dec;26 (Suppl E):71–77. [PubMed]
  • Poirier R. Comparative study of clarithromycin and roxithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 1991 Feb;27 (Suppl A):109–116. [PubMed]
  • Koulla-Shiro S, Kuaban C, Auckenthaler R, Belec L, Ngu JL. Adult response to initial treatment with ampicillin in community acquired pneumonia in Yaoundé, Cameroon. Cent Afr J Med. 1993 Sep;39(9):188–192. [PubMed]
  • Gaillat J, Bru JP, Sedallian A. Penicillin G/ofloxacin versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1994 Aug;13(8):639–644. [PubMed]
  • Uzun O, Hayran M, Akova M, Gür D, Akalin HE. Efficacy of a three-day course of azithromycin in the treatment of community-acquired pneumococcal pneumonia. Preliminary report. J Chemother. 1994 Feb;6(1):53–57. [PubMed]
  • Jang TN, Liu CY, Wang FD, Yang SP, Fung CP. A randomized comparative study on the safety and efficacy of clarithromycin and erythromycin in treating community-acquired pneumonia. Zhonghua Yi Xue Za Zhi (Taipei) 1995 Apr;55(4):302–306. [PubMed]
  • Rizzato G, Montemurro L, Fraioli P, Montanari G, Fanti D, Pozzoli R, Magliano E. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J. 1995 Mar;8(3):398–402. [PubMed]
  • Oh HM, Ng AW, Lee SK. Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Singapore Med J. 1996 Jun;37(3):255–257. [PubMed]
  • Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest. 1996 Oct;110(4):965–971. [PubMed]
  • Genné D, Siegrist HH, Humair L, Janin-Jaquat B, de Torrenté A. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1997 Nov;16(11):783–788. [PubMed]
  • Ho A, Leung R, Lai CK, Chan TH, Chan CH. Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime. Respiration. 1997;64(3):224–228. [PubMed]
  • Cabellos C, Ariza J, Barreiro B, Tubau F, Liñares J, Pallarés R, Manresa F, Gudiol F. Current usefulness of procaine penicillin in the treatment of pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 1998 Apr;17(4):265–268. [PubMed]
  • Rhew DC, Hackner D, Henderson L, Ellrodt AG, Weingarten SR. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest. 1998 Jan;113(1):142–146. [PubMed]
  • Speich R, Imhof E, Vogt M, Grossenbacher M, Zimmerli W. Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia. Eur J Clin Microbiol Infect Dis. 1998 May;17(5):313–317. [PubMed]
  • Wallace RJ, Jr, Martin RR, Quinones FJ, Greenberg SB. Ceforanide and cefazolin therapy of pneumonia: comparative clinical trial. Antimicrob Agents Chemother. 1981 Nov;20(5):648–652. [PMC free article] [PubMed]
  • Grieco MM, Lange M, Daniels JA, Den M, Amaram N, Kornfeld H. Single-blind controlled study of ceftizoxime and cefamandole in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):223–225. [PubMed]
  • Wallace RJ, Jr, Niefield SL, Waters S, Waters B, Awe RJ, Wiss K, Martin RR, Greenberg SB. Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia. Antimicrob Agents Chemother. 1982 Feb;21(2):231–235. [PMC free article] [PubMed]
  • Keeton GR, Kehoe B, Phillips SW, Daya H. Ceftazidime and cefamandole in the treatment of pneumonia. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):27–30. [PubMed]
  • Geckler RW, McCormack GD, Goodman JS. Comparison of cefonicid and cefamandole for the treatment of community-acquired infections of the lower respiratory tract. Rev Infect Dis. 1984 Nov-Dec;6 (Suppl 4):S847–S852. [PubMed]
  • Weber DJ, Calderwood SB, Karchmer AW, Pennington JE. Ampicillin versus cefamandole as initial therapy for community-acquired pneumonia. Antimicrob Agents Chemother. 1987 Jun;31(6):876–882. [PMC free article] [PubMed]
  • Carbon C, Léophonte P, Petitpretz P, Chauvin JP, Hazebroucq J. Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1992 Apr;36(4):833–839. [PMC free article] [PubMed]
  • Kissling M. Cefetamet pivoxil in community-acquired pneumonia: an overview. Curr Med Res Opin. 1992;12(10):631–639. [PubMed]
  • Wiesner B, Wilen-Rosenqvist G, Lehtonen L. Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia. Arzneimittelforschung. 1993 Sep;43(9):1014–1017. [PubMed]
  • Liippo K, Tala E, Puolijoki H, Brückner OJ, Rodrig J, Smits JP. A comparative study of dirithromycin and erythromycin in bacterial pneumonia. J Infect. 1994 Mar;28(2):131–139. [PubMed]
  • Williams D, Perri M, Zervos MJ. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1994 Apr;13(4):293–298. [PubMed]
  • De Palma M, Rocchi D, Canepa G, Peri A, Cantone V. Single daily dose of cefodizime in patients with community-acquired pneumonia: an open-label, controlled, randomized study. The Italian Multicentre Community-Acquired Pneumonia Group. Clin Ther. 1995 May-Jun;17(3):413–424. [PubMed]
  • Aubier M, Lode H, Gialdroni-Grassi G, Huchon G, Hosie J, Legakis N, Regamey C, Segev S, Vester R, Wijnands WJ, et al. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. J Antimicrob Chemother. 1996 May;37 (Suppl A):73–82. [PubMed]
  • Hernández JM, Sides GD, Conforti PM, Smietana MG. Clinical efficacy of dirithromycin in patients with bacteremic pneumonia. Clin Ther. 1996 Nov-Dec;18(6):1128–1138. [PubMed]
  • Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. Chest. 1996 Dec;110(6):1499–1506. [PubMed]
  • Portier H, May T, Proust A. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group. J Antimicrob Chemother. 1996 May;37 (Suppl A):83–91. [PubMed]
  • Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother. 1996 May;37 (Suppl A):145–160. [PubMed]
  • Donowitz GR, Brandon ML, Salisbury JP, Harman CP, Tipping DM, Urick AE, Talbot GH. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clin Ther. 1997 Sep-Oct;19(5):936–953. [PubMed]
  • Drehobl M, Bianchi P, Keyserling CH, Tack KJ, Griffin TJ. Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia. Antimicrob Agents Chemother. 1997 Jul;41(7):1579–1583. [PMC free article] [PubMed]
  • Ragnar Norrby S. Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group. J Antimicrob Chemother. 1997 Apr;39(4):499–508. [PubMed]
  • O'Doherty B, Dutchman DA, Pettit R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 1997 Dec;40 (Suppl A):73–81. [PubMed]
  • Aubier M, Verster R, Regamey C, Geslin P, Vercken JB. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group. Clin Infect Dis. 1998 Jun;26(6):1312–1320. [PubMed]
  • Salvarezza CR, Mingrone H, Fachinelli H, Kijanczuk S. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. J Antimicrob Chemother. 1998 Mar;41 (Suppl B):75–80. [PubMed]
  • Trémolières F, de Kock F, Pluck N, Daniel R. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):447–453. [PubMed]
  • Zervos M, Nelson M. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group. Antimicrob Agents Chemother. 1998 Apr;42(4):729–733. [PMC free article] [PubMed]
  • Grossman RF, Campbell DA, Landis SJ, Garber GE, Murray G, Stiver HG, Saginur R, McIvor RA, Laforge J, Rotstein C, et al. Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin. J Antimicrob Chemother. 1999 Apr;43(4):549–554. [PubMed]
  • Moola S, Hagberg L, Churchyard GA, Dylewski JS, Sedani S, Staley H. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. Chest. 1999 Oct;116(4):974–983. [PubMed]
  • Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther. 1999 Jan;21(1):103–117. [PubMed]
  • Blaser MJ, Klaus BD, Jacobson JA, Kasworm E, LaForce FM. Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia. Antimicrob Agents Chemother. 1983 Aug;24(2):163–167. [PMC free article] [PubMed]
  • Cassell GH, Drnec J, Waites KB, Pate MS, Duffy LB, Watson HL, McIntosh JC. Efficacy of clarithromycin against Mycoplasma pneumoniae. J Antimicrob Chemother. 1991 Feb;27 (Suppl A):47–59. [PubMed]
  • Morales JO, Snead H. Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients. Am J Med. 1994 Aug 15;97(2A):28–33. [PubMed]
  • Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):219–223. [PubMed]
  • Higuera F, Hidalgo H, Feris J, Giguere G, Collins JJ. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 1996 Mar;37(3):555–564. [PubMed]
  • Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1999 Feb 8;159(3):266–270. [PubMed]
  • Schönwald S, Kuzman I, Oresković K, Burek V, Skerk V, Car V, Bozinović D, Culig J, Radosević S. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome--a randomized study. Infection. 1999 May-Jun;27(3):198–202. [PubMed]
  • Sherer Y, Bakshi E, Rotman P, Levy Y, Shoenfeld Y. Comparative clinical study of cefonicid, chloramphenicol, and penicillin in community-acquired pneumonia. Int J Mol Med. 1998 Sep;2(3):343–348. [PubMed]
  • Morandini G, Perduca M, Zannini G, Foschino MP, Miragliotta G, Carnimeo NS. Clinical efficacy of azithromycin in lower respiratory tract infections. J Chemother. 1993 Feb;5(1):32–36. [PubMed]
  • Finch RG, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs. 1998 Jan;55(1):31–45. [PubMed]
  • Moreno S, García-Leoni ME, Cercenado E, Diaz MD, Bernaldo de Quirós JC, Bouza E. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis. 1995 May;20(5):1195–1200. [PubMed]
  • Jackson MA, Burry VF, Olson LC, Duthie SE, Kearns GL. Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr Infect Dis J. 1996 Nov;15(11):1049–1051. [PubMed]
  • Amsden GW. Pneumococcal macrolide resistance--myth or reality? J Antimicrob Chemother. 1999 Jul;44(1):1–6. [PubMed]
  • Pérez-Trallero E. Pneumococcal macrolide resistance-not a myth. J Antimicrob Chemother. 2000 Mar;45(3):401–403. [PubMed]
  • Carbon C, Poole MD. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J Chemother. 1999 Apr;11(2):107–118. [PubMed]
  • Moss PJ, Finch RG. The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults. Thorax. 2000 Jan;55(1):83–85. [PMC free article] [PubMed]
  • Sportel JH, Koëter GH, van Altena R, Löwenberg A, Boersma WG. Relation between beta-lactamase producing bacteria and patient characteristics in chronic obstructive pulmonary disease (COPD). Thorax. 1995 Mar;50(3):249–253. [PMC free article] [PubMed]
  • Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997 Dec 17;278(23):2080–2084. [PubMed]
  • Simpson JC, Macfarlane JT, Watson J, Woodhead MA. A national confidential enquiry into community acquired pneumonia deaths in young adults in England and Wales. British Thoracic Society Research Committee and Public Health Laboratory Service. Thorax. 2000 Dec;55(12):1040–1045. [PMC free article] [PubMed]
  • Schülin T, Wennersten CB, Ferraro MJ, Moellering RC, Jr, Eliopoulos GM. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother. 1998 Jun;42(6):1520–1523. [PMC free article] [PubMed]
  • Burgess DS, Lewis JS., 2nd Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther. 2000 Jul;22(7):872–878. [PubMed]
  • Edelstein PH. Antimicrobial chemotherapy for Legionnaires disease: time for a change. Ann Intern Med. 1998 Aug 15;129(4):328–330. [PubMed]
  • Wallace RJ, Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis. 1995 Mar;171(3):747–750. [PubMed]
  • Plemmons RM, McAllister CK, Garces MC, Ward RL. Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient: case report and analysis of interactions among clarithromycin, rifampin, and cyclosporine. Clin Infect Dis. 1997 May;24(5):995–997. [PubMed]
  • Léophonte P, Veyssier P. La lévofloxacine dans le traitement des pneumonies communautaires à pneumocoque. Presse Med. 1999 Nov 20;28(36):1975–1979. [PubMed]
  • Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis. 1998;30(4):397–404. [PubMed]
  • MacGregor RR, Graziani AL. Oral administration of antibiotics: a rational alternative to the parenteral route. Clin Infect Dis. 1997 Mar;24(3):457–467. [PubMed]
  • Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther. 1999 Jul;6(4):217–222. [PubMed]
  • Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):872–877. [PubMed]
  • Heffner JE, McDonald J, Barbieri C, Klein J. Management of parapneumonic effusions. An analysis of physician practice patterns. Arch Surg. 1995 Apr;130(4):433–438. [PubMed]
  • Light RW. A new classification of parapneumonic effusions and empyema. Chest. 1995 Aug;108(2):299–301. [PubMed]
  • Heffner JE, Brown LK, Barbieri C, DeLeo JM. Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med. 1995 Jun;151(6):1700–1708. [PubMed]
  • Nguyen-van-Tam JS, Nicholson KG. Influenza deaths in Leicestershire during the 1989-90 epidemic: implications for prevention. Epidemiol Infect. 1992 Jun;108(3):537–545. [PMC free article] [PubMed]
  • Ahmed AE, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet. 1995 Sep 2;346(8975):591–595. [PubMed]
  • Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994 Sep 22;331(12):778–784. [PubMed]
  • Nguyen-Van-Tam JS, Nicholson KG. Influenza immunization; vaccine offer, request and uptake in high-risk patients during the 1991/2 season. Epidemiol Infect. 1993 Oct;111(2):347–355. [PMC free article] [PubMed]
  • Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJ, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ. 1993 Oct 16;307(6910):988–990. [PMC free article] [PubMed]
  • Fedson DS, Wajda A, Nicol JP, Hammond GW, Kaiser DL, Roos LL. Clinical effectiveness of influenza vaccination in Manitoba. JAMA. 1993 Oct 27;270(16):1956–1961. [PubMed]
  • Foster DA, Talsma A, Furumoto-Dawson A, Ohmit SE, Margulies JR, Arden NH, Monto AS. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol. 1992 Aug 1;136(3):296–307. [PubMed]
  • Nichol KL. Complications of influenza and benefits of vaccination. Vaccine. 1999 Jul 30;17 (Suppl 1):S47–S52. [PubMed]
  • Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999 Mar 2;130(5):397–403. [PubMed]
  • Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994 Dec 7;272(21):1661–1665. [PubMed]
  • Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995 Oct 1;123(7):518–527. [PubMed]
  • Palache AM, Beyer WE, Lüchters G, Völker R, Sprenger MJ, Masurel N. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine. 1993;11(9):892–908. [PubMed]
  • Beyer WE, de Bruijn IA, Palache AM, Westendorp RG, Osterhaus AD. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med. 1999 Jan 25;159(2):182–188. [PubMed]
  • Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999 Mar 10;281(10):908–913. [PubMed]
  • Treanor JJ, Mattison HR, Dumyati G, Yinnon A, Erb S, O'Brien D, Dolin R, Betts RF. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med. 1992 Oct 15;117(8):625–633. [PubMed]
  • García E, Arrecubieta C, Muñoz R, Mollerach M, López R. A functional analysis of the Streptococcus pneumoniae genes involved in the synthesis of type 1 and type 3 capsular polysaccharides. Microb Drug Resist. 1997 Spring;3(1):73–88. [PubMed]
  • Sniadack DH, Schwartz B, Lipman H, Bogaerts J, Butler JC, Dagan R, Echaniz-Aviles G, Lloyd-Evans N, Fenoll A, Girgis NI, et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children--implications for vaccine strategies. Pediatr Infect Dis J. 1995 Jun;14(6):503–510. [PubMed]
  • Honkanen PO, Keistinen T, Kivelä SL. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med. 1996 Jan 22;156(2):205–208. [PubMed]
  • Hedlund JU, Kalin ME, Ortqvist AB, Henrichsen J. Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia. Arch Intern Med. 1994 Sep 12;154(17):1961–1965. [PubMed]
  • Davidson M, Bulkow LR, Grabman J, Parkinson AJ, Chamblee C, Williams WW, Lanier AP, Schiffman G. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med. 1994 Oct 10;154(19):2209–2214. [PubMed]
  • Shelly MA, Jacoby H, Riley GJ, Graves BT, Pichichero M, Treanor JJ. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun. 1997 Jan;65(1):242–247. [PMC free article] [PubMed]
  • Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, Detsky AS, Kapoor WN. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med. 1994 Dec 12;154(23):2666–2677. [PubMed]
  • Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med. 1999 Nov 8;159(20):2437–2442. [PubMed]
  • Melbye H, Berdal BP, Straume B, Russell H, Vorland L, Thacker WL. Pneumonia--a clinical or radiographic diagnosis? Etiology and clinical features of lower respiratory tract infection in adults in general practice. Scand J Infect Dis. 1992;24(5):647–655. [PubMed]
  • Berntsson E, Lagergård T, Strannegård O, Trollfors B. Etiology of community-acquired pneumonia in out-patients. Eur J Clin Microbiol. 1986 Aug;5(4):446–447. [PubMed]
  • Michetti G, Pugliese C, Bamberga M, Ori Belometti M, Villa R, Maggi L, Ranzanici S, Perani V, Farina C, Moioli F, et al. Community-acquired pneumonia: is there difference in etiology between hospitalized and out-patients? Minerva Med. 1995 Sep;86(9):341–351. [PubMed]
  • Blanquer J, Blanquer R, Borrás R, Nauffal D, Morales P, Menéndez R, Subías I, Herrero L, Redón J, Pascual J. Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. Thorax. 1991 Jul;46(7):508–511. [PMC free article] [PubMed]
  • Almirall J, Bolíbar I, Vidal J, Sauca G, Coll P, Niklasson B, Bartolomé M, Balanzó X. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J. 2000 Apr;15(4):757–763. [PubMed]
  • Berntsson E, Blomberg J, Lagergård T, Trollfors B. Etiology of community-acquired pneumonia in patients requiring hospitalization. Eur J Clin Microbiol. 1985 Jun;4(3):268–272. [PubMed]
  • Lévy M, Dromer F, Brion N, Leturdu F, Carbon C. Community-acquired pneumonia. Importance of initial noninvasive bacteriologic and radiographic investigations. Chest. 1988 Jan;93(1):43–48. [PubMed]
  • Burman LA, Trollfors B, Andersson B, Henrichsen J, Juto P, Kallings I, Lagergård T, Möllby R, Norrby R. Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens. J Infect Dis. 1991 May;163(5):1087–1093. [PubMed]
  • Hone R, Haugh C, O'Connor B, Hollingsworth J. Legionella: an infrequent cause of adult community acquired pneumonia in Dublin. Ir J Med Sci. 1989 Sep;158(9):230–232. [PubMed]
  • Ruf B, Schürmann D, Horbach I, Fehrenbach FJ, Pohle HD. Incidence and clinical features of community-acquired legionellosis in hospitalized patients. Eur Respir J. 1989 Mar;2(3):257–262. [PubMed]
  • Pareja A, Bernal C, Leyva A, Piedrola G, Maroto MC. Etiologic study of patients with community-acquired pneumonia. Chest. 1992 May;101(5):1207–1210. [PubMed]
  • Holmberg H. Aetiology of community-acquired pneumonia in hospital treated patients. Scand J Infect Dis. 1987;19(5):491–501. [PubMed]
  • Aubertin J, Dabis F, Fleurette J, Bornstein N, Salamon R, Brottier E, Brune J, Vincent P, Migueres J, Jover A, et al. Prevalence of legionellosis among adults: a study of community-acquired pneumonia in France. Infection. 1987;15(5):328–331. [PubMed]
  • Blasi F, Cosentini R, Raccanelli R, Rinaldi A, Denti F, Loprete F, Allegra L. Emerging pathogens of community-acquired pneumonia: a two-year prospective study. J Chemother. 1995 Nov;7 (Suppl 4):115–116. [PubMed]
  • Socan M, Marinic-Fiser N, Kraigher A, Kotnik A, Logar M. Microbial aetiology of community-acquired pneumonia in hospitalised patients. Eur J Clin Microbiol Infect Dis. 1999 Nov;18(11):777–782. [PubMed]
  • Lorente ML, Falguera M, Nogués A, González AR, Merino MT, Caballero MR. Diagnosis of pneumococcal pneumonia by polymerase chain reaction (PCR) in whole blood: a prospective clinical study. Thorax. 2000 Feb;55(2):133–137. [PMC free article] [PubMed]
  • Mundy LM, Auwaerter PG, Oldach D, Warner ML, Burton A, Vance E, Gaydos CA, Joseph JM, Gopalan R, Moore RD, et al. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1309–1315. [PubMed]
  • Bates JH, Campbell GD, Barron AL, McCracken GA, Morgan PN, Moses EB, Davis CM. Microbial etiology of acute pneumonia in hospitalized patients. Chest. 1992 Apr;101(4):1005–1012. [PubMed]
  • Olaechea PM, Quintana JM, Gallardo MS, Insausti J, Maraví E, Alvarez B. A predictive model for the treatment approach to community-acquired pneumonia in patients needing ICU admission. Intensive Care Med. 1996 Dec;22(12):1294–1300. [PubMed]
  • Ortqvist A, Sterner G, Nilsson JA. Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis. 1985;17(4):377–386. [PubMed]
  • Rello J, Quintana E, Ausina V, Net A, Prats G. A three-year study of severe community-acquired pneumonia with emphasis on outcome. Chest. 1993 Jan;103(1):232–235. [PubMed]
  • Almirall J, Mesalles E, Klamburg J, Parra O, Agudo A. Prognostic factors of pneumonia requiring admission to the intensive care unit. Chest. 1995 Feb;107(2):511–516. [PubMed]
  • Sörensen J, Forsberg P, Håkanson E, Maller R, Sederholm C, Sörén L, Carlsson C. A new diagnostic approach to the patient with severe pneumonia. Scand J Infect Dis. 1989;21(1):33–41. [PubMed]
  • Montejo Baranda M, Corral Carranceja J, Aguirre Errasti C. Q fever in the Basque Country: 1981-1984. Rev Infect Dis. 1985 Sep-Oct;7(5):700–701. [PubMed]
  • Marrie TJ, Haldane EV, Faulkner RS, Kwan C, Grant B, Cook F. The importance of Coxiella burnetii as a cause of pneumonia in Nova Scotia. Can J Public Health. 1985 Jul-Aug;76(4):233–236. [PubMed]
  • Feldman C, Ross S, Mahomed AG, Omar J, Smith C. The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy. Respir Med. 1995 Mar;89(3):187–192. [PubMed]
  • Potgieter PD, Hammond JM. Etiology and diagnosis of pneumonia requiring ICU admission. Chest. 1992 Jan;101(1):199–203. [PubMed]
  • Thompson JE. Community acquired pneumonia in north eastern Australia--a hospital based study of aboriginal and non-aboriginal patients. Aust N Z J Med. 1997 Feb;27(1):59–61. [PubMed]
  • Boonsawat W, Boonma P, Tangdajahiran T, Paupermpoonsiri S, Wongpratoom W, Romphryk A. Community-acquired pneumonia in adults at Srinagarind Hospital. J Med Assoc Thai. 1990 Jun;73(6):345–352. [PubMed]
  • Lee KH, Hui KP, Tan WC, Lim TK. Severe community-acquired pneumonia in Singapore. Singapore Med J. 1996 Aug;37(4):374–377. [PubMed]

Articles from Thorax are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...